Table of Contents
Dow Jones futures rose solidly Monday morning, while S&P 500 futures and Nasdaq futures jumped, with crude oil, Treasury yields and Bitcoin also recouping some of Friday’s big losses. All eyes are on the newly discovered omicron Covid variant following Friday’s sell-off.
Li Auto jumped early Monday, flashing at least an early buy signal on mixed Q3 results but bullish guidance. Later this week, Li Auto (LI) and Chinese EV startups Nio (NIO) and Xpeng (XPEV) are likely to release November delivery figures. China EV giant BYD Co. (BYDDF) may come slightly later, with Tesla (TSLA) China sales figures eventually following.
The stock market rally was hit from all directions last week, with the major indexes tumbling below key levels Friday on the new omicron Covid variant, with crude oil prices and Treasury yields plunging. The current uncertainty makes it difficult to navigate the stock market rally. Investors should be playing more defense than offense until conditions clearly improve. More clarity on the new omicron variant is needed.
The video embedded in this article analyzed a pivotal market week and discussed PFE stock, Ovintiv (OVV) and Li Auto.
Dow Jones Futures Today
Dow Jones futures rose 0.7% vs. fair value. S&P 500 futures advanced 0.9% and Nasdaq 100 futures jumped 1.1%. Those are slightly off their overnight highs.
The 10-year Treasury yield rose 6 basis points to 1.55%.
U.S. crude oil prices rebounded 5% after Friday’s 13% plunge, though natural gas prices fell sharply. OPEC+ on Sunday delayed some technical meetings set for Monday-Tuesday to Wednesday-Thursday so the market can digest the impact of the new Covid variant.
Bitcoin rose above $57,000, bolstering a modest “risk on” sentiment after Friday’s sharp sell-off in cryptocurrencies. But it’s off overnight highs of above $58,000.
Remember that overnight action in Dow futures and elsewhere doesn’t necessarily translate into actual trading in the next regular stock market session.
Omicron Coronavirus: Covid Variant Of Concern
A new coronavirus variant with a large number of mutations, first detected in South Africa, is raising concerns. It’s unclear if the B.1.1529 Covid variant, dubbed the omicron variant on Friday, is more deadly or infectious than prior strains, or whether vaccinations or prior Covid infection provide substantial protection.
The World Health Organization noted that the omicron variant appears to have a higher risk of reinfection for people who have already had Covid-19. The WHO declared it a “variant of concern,” the first such designation since the delta variant a year ago.
However, a coronavirus adviser to the South Africa government as well as the Pretoria doctor who sounded the alarm about the Omicron variant said that cases generally seem to be “mild.”
There are reasons to believe that anti-viral pills, such as those made by Pfizer and Merck (MRK), would retain effectiveness vs. the latest Covid strain.
The U.S., U.K., European Union, Australia, Israel and Singapore have suspended flights or entry from southern Africa.
Dutch officials on Sunday reported 13 omicron Covid cases among travelers from South Africa to the Netherlands.
The U.K., Belgium, Australia, Italy, Hong Kong and Israel are among countries that have identified a handful of omicron Covid cases.
Coronavirus Vaccine Stocks
Pfizer partner BioNTech said it will take two weeks to see how effective its vaccine is vs. the omicron Covid variant. Moderna said it could have a Covid vaccine designed for the omicron variant by early 2022. Moderna’s CEO said Monday that the omicron Covid variant appears to be highly infectious.
On Nov. 19, the FDA approved Moderna or Pfizer booster shots for all adults. That came soon after the FDA approved the Pfizer/BioNTech vaccine for children aged 5-11, after already approving the Covid vaccine for adolescents aged 12-15.
Pfizer and partner BioNTech, along with rival mRNA coronavirus vaccine maker Moderna, jumped Friday on the omicron Covid variant, also called Nu Covid. Pfizer also is benefitting from Merck reporting even-lower efficacy from its antiviral Covid pill. A Pfizer Covid oral drug is much more effective.
PFE stock jumped 6.1% on Friday to 54, gapping above a 51.96 buy point, according to MarketSmith analysis. However, Pfizer stock has surged for six straight weeks off the bottom of its cup base. A pullback wouldn’t be a surprise.
PFE stock rose modestly early Monday, however.
MRNA stock gapped above its 50-day line, breaking a trend line with a 21% gain. BNTX stock, which cleared its 50-day line earlier in the week, soared 14%. Both Moderna stock and BioNTech could be deemed early entries. But investors might want to see more strength from Moderna and a post-gap up consolidation from BNTX stock.
Moderna stock jumped 9% in Monday’s premarket trading and BNTX stock 5%.
Covid Cases Rising
Coronavirus cases had already been ramping up worldwide for the past several weeks, notably in Europe. Austria began a lockdown in the past week.
Coronavirus cases worldwide reached 261.92 million. Covid-19 deaths topped 5.21 million.
Coronavirus cases in the U.S. have hit 49.09 million, with deaths above 799,000. U.S. cases, after picking up for a couple of weeks, appeared to be leveling off shortly before Thanksgiving. Will the holiday travel spur another upsurge in cases next week? Coronavirus deaths in the U.S. have continued to fall.
These Sectors Lead Sell-Off As New Covid Variant Emerges
Stock Market Rally Last Week
The stock market rally had a rough holiday-shortened week, with broad-based losses.
The Dow Jones Industrial Average gave up 2% in last week’s stock market trading, all driven by Friday’s 2.5% decline. The S&P 500 index shed 2.2%. The Nasdaq composite skidded 3.5%. The small-cap Russell 2000 tumbled 4.6%.
Crude oil futures plunged 13% on Friday. The 10-year Treasury yield lost 4 basis points to 1.49% for the week. But the benchmark yield dived 15 basis points Friday after nearly hitting a six-month high Wednesday intraday.
Among the best ETFs, the Innovator IBD 50 ETF (FFTY) plunged 5.9%, while the Innovator IBD Breakout Opportunities ETF (BOUT) gave up 3.5%. The iShares Expanded Tech-Software Sector ETF (IGV) slumped 5%. The VanEck Vectors Semiconductor ETF (SMH) retreated 4.1%.
SPDR S&P Metals & Mining ETF (XME) fell 3.2% and Global X U.S. Infrastructure Development ETF (PAVE) declined 2.1%. U.S. Global Jets ETF (JETS) tumbled 7%. SPDR S&P Homebuilders ETF (XHB) slid 2%. The Energy Select SPDR ETF (XLE) rose 1.3%, but tumbled 4.3% on Friday with many shale plays faring far worse. The Financial Select SPDR ETF (XLF) lost 1%, skidding 3.7% on Friday.
Five Best Chinese Stocks To Watch Now
Li Auto Stock
Li Auto reported a wider-than-expected Q3 loss, but revenue shot up 210% and the hybrid SUV maker gave bullish guidance. It sees Q4 deliveries of 30,000-32,000, up 107%-121% vs. a year earlier and up from 25,116 deliveries in Q3. Total revenue should jump 113%-127% in local currency to $1.37 billion-$1.46 billion.
Li Auto shot up 9% to 35.26. That’s above the official 34.93 handle buy point and topping an early entry above 33.
Xpeng stock is holding above a 48.08 buy point and 50.50 alternative entry after surging on earnings in the past week. Tesla and BYD stock could be working on new consolidations, both closing Friday near their 21-day lines. Nio stock has fallen back below its 200-day line.
Tesla CEO Elon Musk, in a “leaked” email to employees, suggested the EV giant may push some Q4 deliveries from the typical end-of-quarter crush into early 2022, in a bid to lower shipping costs. “Leaked” Musk emails often spur analysts to lower quarterly delivery targets. The upcoming Austin and Berlin plants should eventually ease some of the Tesla delivery crush in the U.S., Europe and China.
Tesla Berlin will begin production in December, Automobilwoche reported Sunday. Regulators are expected to give final approval to the plant with days. Production is seen picking up in January, but it at a relatively slow ramp in early 2022.
Tesla stock, Xpeng and Nio rose modestly before the open.
Market Rally Analysis
In the past week, the stock market rally started a major sell-off in highly valued growth stocks, especially software, while energy stocks and banks rebounded. The new Covid variant sent stocks sharply lower on Friday, especially oil and financials, as crude prices and Treasury yields tumbled. Travel stocks also were hard hit, while retailers extended a recent retreat. Coronavirus plays bounced, while software names held up relatively well.
The Nasdaq composite and S&P 500 gapped below their 21-day lines after both found support at that key level earlier in the week. The Dow Jones, which was up modestly through Wednesday, gapped below its 50-day line on Friday.
The Russell 2000 tumbled below its 50-day and 200-day moving averages. The small-cap index is a decent proxy for market breadth, which has weakened considerably. Losers trounced winners 4-to-1 on the Nasdaq Friday, and by 5-to-1 on the NYSE. The advance/decline lines have deteriorated in the past few weeks.
The CBOE Volatility Index, or VIX, spiked 54% to 28.62, hitting a 10-month high. Extreme moves in the so-called market fear gauge could raise the odds of at least a short-term market bottom. But it doesn’t have to happen right away and it doesn’t have to last.
There’s a lot of uncertainty right now regarding the market rally and which sectors will lead and lag. Market action is likely to be headline driven. How dangerous is the omicron Covid variant? That will inform governments’ decisions on travel bans and restrictions and whether or not people adjust their behavior once again. A major outbreak could trigger new government and business shutdowns, roiling supply chains once again and sending commodity prices on a longer slide.
Perhaps all these fears are overdone. Goldman Sachs, in a Friday night note, said “this mutation is unlikely to be more malicious and that the existing vaccines will most likely continue to be effective in preventing hospitalizations and deaths.” Goldman added, “we do not think that the new variant is sufficient reason to make major portfolio changes.”
Time The Market With IBD’s ETF Market Strategy
What To Do Now
The whipsaw, downside action in the major indexes, various sectors and leading stocks is not conducive to new buys. Sure, if the overall stock market rally or specific sectors rebound, buying now will likely turn out well. But with so much uncertainty regarding the new omicron Covid variant, inflation, supply chains and more, the odds are not especially favorable.
Dow Jones futures signal a market rebound at Monday’s open. But that doesn’t mean the bounce will continue.
Investors should review their holdings and ditch losers. If you got caught out in Friday’s gap-down losses and didn’t act, don’t continue to freeze.
Take more of a defensive posture with all of your holdings and portfolio. Don’t necessarily be in a rush to sell everything, unless all your stocks are triggering losses.
When market conditions do shore up, whether it’s next week or next year, you want to be ready financially and mentally to take advantage.
Read The Big Picture every day to stay in sync with the market direction and leading stocks and sectors.
Please follow Ed Carson on Twitter at @IBD_ECarson for stock market updates and more.
YOU MAY ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
Five Diverse Stocks Near Buy Points